TSHR and hepatocellular carcinoma: However, it was not until 2018 that Shih and coworkers demonstrated that the levels of TSHR predicted clinical outcomes of patients with hepatocellular carcinoma (HCC), of which poorer survival rates were observed in those with higher TSHR expression, and the presence of TSH altered sensitivity of HCC cells to cisplatin, a chemotherapeutic drug for HCC, in vitro [43].